A financial giant has made a conspicuous bearish move on Pfizer. Our analysis of options history for Pfizer PFE revealed 10 unusual trades. Delving into the details, we found 30% of traders were bullish, while 70% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $8,504,440, and 3 were calls, valued at $80,240.
Projected Price Targets
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $50.0 for Pfizer, spanning the last three months.
Analyzing Volume & Open Interest
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Pfizer's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Pfizer's significant trades, within a strike price range of $20.0 to $50.0, over the past month.
Pfizer Option Activity Analysis: Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| PFE | PUT | TRADE | BULLISH | 11/10/23 | $35.00 | $4.2M | 55 | 1 |
| PFE | PUT | TRADE | NEUTRAL | 11/10/23 | $35.00 | $4.0M | 55 | 18.5K |
| PFE | PUT | TRADE | BEARISH | 06/21/24 | $50.00 | $78.0K | 571 | 0 |
| PFE | PUT | TRADE | NEUTRAL | 01/19/24 | $50.00 | $67.7K | 228 | 0 |
| PFE | PUT | TRADE | NEUTRAL | 01/19/24 | $50.00 | $48.6K | 228 | 60 |
Current Position of Pfizer
- Trading volume stands at 13,151,033, with PFE's price down -2.0%, positioned at $30.62. RSI indicators show the stock to be may be approaching oversold. Earnings announcement expected in 83 days.
What Analysts Are Saying About Pfizer:
- Consistent in their evaluation, Barclays keeps a Equal-Weight rating on Pfizer with a target price of $34.
- UBS has revised its rating downward to Neutral, adjusting the price target to $34.
- Maintaining their stance, Citigroup continues to hold a Neutral rating for Pfizer, targeting a price of $35.
- JP Morgan has decided to maintain their Neutral rating on Pfizer, which currently sits at a price target of $34.
- Wells Fargo persists with their Equal-Weight rating on Pfizer, maintaining a target price of $35.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Pfizer options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
